DISC MEDICINE INC (IRON)

US2546041011 - Common Stock

64.96  +1.45 (+2.29%)

After market: 64.96 0 (0%)

News Image
11 days ago - Disc Medicine Inc

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...

News Image
12 days ago - Disc Medicine Inc

Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study...

News Image
16 days ago - Disc Medicine Inc

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

WATERTOWN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has obtained a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. This financing provides funding options to support anticipated key catalysts, including the expected initiation of a confirmatory study of bitopertin in erythropoietic protoporphyria (EPP), a Phase 2 study of DISC-0974 in anemia of myelofibrosis (MF) and a multiple dose study in anemia of non-dialysis dependent chronic kidney disease (NDD-CKD), and a Phase 2 study of DISC-3405 in polycythemia vera (PV).

News Image
20 days ago - Chartmill

These stocks are gapping in today's session

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

News Image
20 days ago - Disc Medicine Inc

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of...

News Image
23 days ago - Disc Medicine Inc

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...

News Image
a month ago - Disc Medicine Inc

Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...

News Image
a month ago - Disc Medicine Inc

Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

Dr. Rahul Rajan Kaushik is an accomplished technical operations leader with over two decades of expertise in Chemistry, Manufacturing and Controls (CMC)

News Image
a month ago - Disc Medicine Inc

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...

News Image
2 months ago - Market News Video

IRON Crosses Below Key Moving Average Level

News Image
2 months ago - Disc Medicine Inc

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs

News Image
2 months ago - Disc Medicine Inc

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs...

News Image
2 months ago - Market News Video

IRON Crosses Below Key Moving Average Level

News Image
3 months ago - Disc Medicine Inc

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...

News Image
4 months ago - InvestorPlace

IRON Stock Earnings: Disc Medicine Beats EPS for Q2 2024

IRON stock results show that Disc Medicine beat analyst estimates for earnings per share the second quarter of 2024.

News Image
4 months ago - BusinessInsider

IRON Stock Earnings: Disc Medicine Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Disc Medicine (NASDAQ:IRON) just reported results for the second quarter of 202...

News Image
4 months ago - Disc Medicine Inc

Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update

Presented positive data for all three programs at the European Hematology Association (EHA) 2024 Congress; demonstrated potential efficacy for bitopertin...

News Image
5 months ago - Disc Medicine Inc

Disc Medicine Announces Underwritten Offering of Common Stock

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the...

News Image
5 months ago - Disc Medicine Inc

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic...